The value of early intervention in RA--a window of opportunity (Q37847069)

24 August 2017

1 reference

title

The value of early intervention in RA--a window of opportunity (English)

1 reference

24 August 2017

Ferdinand Breedveld

1

1 reference

24 August 2017

publication date

25 February 2011

1 reference

24 August 2017

published in

Clinical Rheumatology

1 reference

24 August 2017

volume

30 Suppl 1

1 reference

24 August 2017

page(s)

S33-9

1 reference

Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Systematic review of studies of productivity loss due to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1638-5

Arthritis and employment research: where are we? Where do we need to go?

21 January 2018

1 reference

12 December 2020

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis

1 reference

12 December 2020

Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.

1 reference

12 December 2020

Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope

1 reference

12 December 2020

Early rheumatoid arthritis -- is there a window of opportunity?

1 reference

12 December 2020

Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time

1 reference

12 December 2020

Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Work disability in rheumatoid arthritis--development over 15 years and evaluation of predictive factors over time

1 reference

12 December 2020

Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration

1 reference

12 December 2020

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

12 December 2020

Can remission be maintained with or without further drug therapy in rheumatoid arthritis?

1 reference

12 December 2020

10.1007/S10067-010-1638-5

Identifiers

DOI

1 reference

24 August 2017

1 reference